news

BioTuesdays: EXOZ selects Curia as CDMO for NCT

Written by eXoZymes | September 11, 2026

eXoZymes (NASDAQ: EXOZ) has entered into an agreement with closely held contract research, development, and manufacturing organization (CDMO) Curia Global to initiate technology transfer and scale-up activities for N-transcaffeoyltyramine (NCT).

Full story here...